A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Sponsor: Janssen Research & Development, LLC
Listed as NCT00210665, this observational or N/A phase trial focuses on Sarcoma and remains ongoing. Sponsored by Janssen Research & Development, LLC, it has been updated 10 times since 2026, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
▶ Show 5 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jul 2017 — Oct 2017 [monthly]
No Longer Available NA
Phase: PHASE3 → NA
-
Feb 2017 — Jul 2017 [monthly]
No Longer Available PHASE3
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .